Approach to the Patient with Elevated Lipoprotein(a)

Area of Science:

• Cardiology
• Genetics
• Lipidology

Background:

• Lipoprotein(a) [Lp(a)] is a prevalent, genetically determined lipoprotein.
• Elevated Lp(a) is independently associated with major cardiovascular events like myocardial infarction and stroke.
• Lp(a) levels are stable and minimally affected by lifestyle, prompting updated screening recommendations.

Purpose of the Study:

• To highlight the clinical importance of Lipoprotein(a) [Lp(a)].
• To outline current management strategies for elevated Lp(a).
• To discuss emerging therapeutic options for Lp(a) lowering.

Main Methods:

• Review of current guidelines and emerging evidence.
• Case-based examples for practical risk assessment and management.
• Discussion of statins, PCSK9 inhibitors, lipid apheresis, and novel therapeutics.

Main Results:

• The 2026 ACC/AHA/Multisociety Dyslipidemia Guideline recommends one-time Lp(a) measurement for all adults.
• Current management focuses on aggressive optimization of traditional risk factors, especially LDL-C reduction.
• Novel Lp(a)-lowering therapies (ASOs, siRNAs) are in Phase 3 clinical trials.

Conclusions:

• Endocrinologists will frequently manage elevated Lp(a) due to new screening guidelines.
• No specific Lp(a)-targeting drugs are approved; management relies on risk factor optimization and adjunctive therapies.
• Emerging therapies show promise for robust Lp(a) reduction, offering future treatment avenues.